Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Luye Pharma GroupFRA:LUP +1.98%83 Equity-to-Asset is 0.49 as of Dec. 2025, which is 4% above its 10-year median of 0.47. GuruFocus rates FRA:LUP with a GF Score™ of 83/100 and a GF Value™ of €0.33. The stock has 5 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Luye Pharma Group ranks worse than 69.81% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Luye Pharma Group's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €1,948.8 Mil. Luye Pharma Group's Total Assets for the quarter that ended in Dec. 2025 was €3,980.1 Mil.
Therefore, Luye Pharma Group's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.49.
The historical rank and industry rank for Luye Pharma Group's Equity-to-Asset or its related term are showing as below:
FRA:LUP'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.38 Med: 0.47 Max: 0.7
Current: 0.45
During the past 13 years, the highest Equity to Asset Ratio of Luye Pharma Group was 0.70. The lowest was 0.38. And the median was 0.47.
FRA:LUP's Equity-to-Asset is ranked worse than 69.81% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs FRA:LUP: 0.45
Luye Pharma Group (FRA:LUP) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Luye Pharma Group Equity-to-Asset Related Terms
Luye Pharma Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Luye Pharma Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Equity-to-Asset of 0.49 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Luye Pharma Group and its competitors. This is near median its historical median of 0.47. Over the past decade, Luye Pharma Group's Equity-to-Asset has ranged from 0.38 to 0.70. According to the industry distribution chart, Luye Pharma Group ranks #703 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 69.8%.
Is Luye Pharma Group's Equity-to-Asset too high?
Luye Pharma Group's current Equity-to-Asset of 0.49 is near median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.38 to a high of 0.70. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Luye Pharma Group's value of 0.49 is 18.3% below this industry median. Based on the distribution chart, Luye Pharma Group ranks #703 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Luye Pharma Group has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #703 out of 1007 companies for Equity-to-Asset. This places Luye Pharma Group in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Luye Pharma Group's value of 0.49 is 18.3% below this benchmark. Historically, Luye Pharma Group's own Equity-to-Asset has ranged from 0.38 to 0.70 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 0.60, Luye Pharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current Equity-to-Asset of 0.49 is 18.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Equity-to-Asset is 0.49, which is near median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Luye Pharma Group (FRA:LUP) has a current Equity-to-Asset of 0.49. The stock's GF Value™ is €0.33, compared to a current price of €0.21 — trading 37.6% below its estimated fair value. The current Equity-to-Asset is 0.49, which is near median its 10-year median of 0.47 and 18.3% below the Drug Manufacturers industry median of 0.60. Luye Pharma Group's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Equity-to-Asset is 0.49 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.21 is trading 37.6% below its estimated GF Value™ of €0.33.
Key valuation signals for FRA:LUP:
Equity-to-Asset: 0.49 (near median its 10-year median of 0.47)
GF Value™: €0.33 vs. price of €0.21 (37.6% below fair value)
Industry Position: 18.3% below the Drug Manufacturers median (#703 of 1007)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
83GF Score
Get the complete analysis for FRA:LUP
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
